Differentiating vasculitis from other diseases: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 52: Line 52:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[ESR]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[MMP|MMP-3]] and [[Matrix metalloproteinase|MMP-9]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Leukocytosis]], [[Anemia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Leukocytosis]], [[Anemia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
Line 73: Line 73:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[ESR]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Pentraxin|Pentraxin 3 (PTX3)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
Line 266: Line 266:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[ESR]], [[CRP]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[LAMP2|LAMP-2 protein autoantibodies]]  
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Leukocytosis]], [[Normochromic anemia]], [[Thrombocytosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Leukocytosis]], [[Normochromic anemia]], [[Thrombocytosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
Line 470: Line 470:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Rash|Generalized rash]], [[Cough]], [[Coryza]], or [[Conjunctivitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Rash|Generalized rash]], [[Cough]], [[Coryza]], or [[Conjunctivitis]]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Rocky Mountain Spotted Fever]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Rocky Mountain Spotted Fever]]<ref name="pmid2504480">{{cite journal| author=Walker DH| title=Rocky Mountain spotted fever: a disease in need of microbiological concern. | journal=Clin Microbiol Rev | year= 1989 | volume= 2 | issue= 3 | pages= 227-40 | pmid=2504480 | doi= | pmc=358117 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2504480  }}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
Line 486: Line 486:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Myocardial]] or conduction abnormalities in [[echocardiography]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Myocardial]] or conduction abnormalities in [[echocardiography]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
!
![[Immunofluorescent]] or [[immunoperoxidase]] staining of ''[[Rickettsia rickettsii infection|R rickettsii]]''
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Clinical criteria and [[tick]] exposure  
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Clinical criteria and [[tick]] exposure  
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Rash on the [[Palms of the hands|palms]] and [[soles]]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Staphylococcal scalded skin syndrome|Staphylococcal Scalded Skin Syndrome]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Staphylococcal scalded skin syndrome|Staphylococcal Scalded Skin Syndrome]]<ref name="pmid27651848">{{cite journal| author=Mishra AK, Yadav P, Mishra A| title=A Systemic Review on Staphylococcal Scalded Skin Syndrome (SSSS): A Rare and Critical Disease of Neonates. | journal=Open Microbiol J | year= 2016 | volume= 10 | issue=  | pages= 150-9 | pmid=27651848 | doi=10.2174/1874285801610010150 | pmc=5012080 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27651848  }}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
Line 500: Line 500:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Anti exfoliatin and [[Alpha toxin|anti alpha-toxin antibodies]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Leukocytosis]] with [[left shift]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Blood culture]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Pneumonia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
!
![[Epidermal bullosa simplex|Intraepidermal blister]], dense superficial perivascular lymphohistiocytic infiltrate 
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Blood culture]] and clinical findings
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Erythroderma|'''Widespread''' skin erythema]], [[Blisters|fluid-filled '''blisters''']]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Toxic Epidermal Necrolysis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Toxic Epidermal Necrolysis]]<ref name="pmid27239294">{{cite journal| author=Hoetzenecker W, Mehra T, Saulite I, Glatz M, Schmid-Grendelmeier P, Guenova E et al.| title=Toxic epidermal necrolysis. | journal=F1000Res | year= 2016 | volume= 5 | issue=  | pages=  | pmid=27239294 | doi=10.12688/f1000research.7574.1 | pmc=4879934 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27239294  }}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
Line 521: Line 521:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[MicroRNA|MicroRNA-124]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Normocytic normochromic anemia|Normochromic normocytic anemia]], [[Eosinophilia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Fluid loss]] and [[electrolyte abnormalities]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Tracheobronchial]] [[inflammation]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
!
![[Necrotic]] [[keratinocytes]] with full-thickness [[epithelial]] [[necrosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Histopathology]] and clinical findings
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Erythematous rash|Erythematous macular rash]] with [[purpuric]] centers
|-
|-
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cardiovascular disease]]
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cardiovascular disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Atrial Myxoma]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Atrial Myxoma]]<ref name="pmid8407260">{{cite journal |vauthors=MacGowan SW, Sidhu P, Aherne T, Luke D, Wood AE, Neligan MC, McGovern E |title=Atrial myxoma: national incidence, diagnosis and surgical management |journal=Ir J Med Sci |volume=162 |issue=6 |pages=223–6 |date=June 1993 |pmid=8407260 |doi= |url=}}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
Line 543: Line 543:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Calretinin]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Mild [[anemia]], [[Leukocytosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑[[Interleukin 6|IL-6]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Atrial]] filling defect larger than a [[thrombus]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Tumor]] location, size, attachment, and mobility in [[echocardiography]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Size, shape, and surface characteristics in [[MRI]]
!
![[Lipid|Lipidic]] cells embedded in a [[vascular]] myxoid stroma
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Echocardiography]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Dyspnea on exertion]], [[Syncope]]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cholesterol Embolism]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cholesterol Embolism]]<ref name="pmid21886725">{{cite journal| author=Avci G, Akoz T, Gul AE| title=Cutaneous cholesterol embolization. | journal=J Dermatol Case Rep | year= 2009 | volume= 3 | issue= 2 | pages= 27-9 | pmid=21886725 | doi=10.3315/jdcr.2009.1031 | pmc=3157794 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21886725  }}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
Line 564: Line 564:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Interleukin 5|IL-5]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Eosinophilia]], [[Leukocytosis]]  
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Eosinophiluria]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Thoracic aorta|Thoracic]] and [[Abdominal aorta|abdominal aortic]] sources of [[embolism]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Atheroembolism]] in [[abdominal aorta]] and the [[lower extremity]] [[arteries]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Excluding an [[intracardiac]] source of [[embolism]] with [[echocardiography]] 
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
!
![[Birefringent]] crystals or biconvex needle-shaped ghostly clefts within the [[arterial]] [[lumen]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Angiography]] 
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Livedo reticularis]],
|-
 
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Segmental arteries|Segmental arterial]] mediolysis
[[Ischemic|Ischemic patches]]
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Segmental arteries|Segmental arterial]] mediolysis<ref name="Chao2009">{{cite journal|last1=Chao|first1=Christine|title=Segmental Arterial Mediolysis|journal=Seminars in Interventional Radiology|volume=26|issue=03|year=2009|pages=224–232|issn=0739-9529|doi=10.1055/s-0029-1225666}}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
Line 585: Line 587:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Leukocytosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Visceral]] artery [[aneurysm]] in [[CT angiography]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Alternating [[aneurysms]] and [[stenoses]] (beading)
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Retroperitoneal hematoma]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
!
!Disruption of the [[smooth muscle]] in the [[Tunica media|media]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Angiography]] 
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hematuria]], [[Ischemic colitis]]
|-
|-
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic disease]]
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Antiphospholipid syndrome|Antiphospholipid Syndrome]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Antiphospholipid syndrome|Antiphospholipid Syndrome]]<ref name="pmid26637701">{{cite journal| author=Chaturvedi S, McCrae KR| title=The antiphospholipid syndrome: still an enigma. | journal=Hematology Am Soc Hematol Educ Program | year= 2015 | volume= 2015 | issue=  | pages= 53-60 | pmid=26637701 | doi=10.1182/asheducation-2015.1.53 | pmc=4877624 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26637701  }}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
Line 607: Line 609:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Antiphospholipid antibodies]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Thrombocytopenia]], [[Hemolytic anemia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Lupus anticoagulant|Lupus anticoagulant (LA)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Stroke]],
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
[[Pulmonary embolism]], [[Budd-Chiari syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Thrombus]] in major [[vessels]]
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Valve thickening, vegetations, or  insufficiency in [[echocardiography]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!Noninflammatory bland [[thrombosis]] without perivascular [[inflammation]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Hx of [[thrombosis]] and [[antiphospholipid antibodies]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Miscarriage]], [[Pulmonary hypertension]]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Juvenile Idiopathic Arthritis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Juvenile Idiopathic Arthritis]]<ref name="pmid22753788">{{cite journal |vauthors=Espinosa M, Gottlieb BS |title=Juvenile idiopathic arthritis |journal=Pediatr Rev |volume=33 |issue=7 |pages=303–13 |date=July 2012 |pmid=22753788 |doi=10.1542/pir.33-7-303 |url=}}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
Line 628: Line 632:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Rheumatoid factor|Rheumatoid factor (RF)]], [[S100A12]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Lymphocytosis]], [[Thrombocytopenia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Myeloid-related proteins 8/14 (MRP8/14)
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Synovial]] [[hypertrophy]], Joint effusions
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Cerebral vasculitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Inflamed [[synovium]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Bone scan|Bone scanning]]
!
![[Vascular congestion]], [[Extravasation|RBC extravasation]], Venular lumen occlusion
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Conventional [[radiography]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Rash|Evanescent rash]], [[Dactylitis]] 
|-
|-
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
Line 664: Line 668:
! rowspan="4" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[ANCA-associated vasculitis]]
! rowspan="4" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[ANCA-associated vasculitis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Microscopic polyangiitis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Microscopic polyangiitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Anti-PR3 [[antibody]], [[MPO|Anti-MPO]] [[antibody]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 685: Line 689:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Granulomatosis with polyangiitis|Granulomatosis with polyangiitis (Wegener’s)]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Granulomatosis with polyangiitis|Granulomatosis with polyangiitis (Wegener’s)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Anti-PR3 [[antibody]], [[MPO|Anti-MPO]] [[antibody]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 692: Line 705:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Eosinophilic granulomatosis with polyangiitis|Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Eotaxin-3
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 705: Line 730:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Eosinophilic granulomatosis with polyangiitis|Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hydralazine]]-associated [[ANCA-associated vasculitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 717: Line 747:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! rowspan="5" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Immune complexes|Immune complex]] small-vessel vasculitis
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Goodpasture disease|Anti-glomerular basement membrane disease]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hydralazine]]-associated [[ANCA-associated vasculitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 734: Line 769:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cryoglobulinemia|Cryoglobulinemic vasculitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[C4A|C4 component]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 747: Line 794:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! rowspan="5" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Immune complexes|Immune complex]] small-vessel vasculitis
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis C virus]]-associated [[Cryoglobulinemia|cryoglobulinemic vasculitis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Goodpasture disease|Anti-glomerular basement membrane disease]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hepatitis C|HCV RNA]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓[[C4A|Serum C4]], Positive [[RF]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Palpable [[purpura]], [[Microscopic hematuria]]
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Henoch-Schönlein purpura|IgA vasculitis (Henoch-Schönlein purpura)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 767: Line 834:
!
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hematuria]]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cryoglobulinemia|Cryoglobulinemic vasculitis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hypocomplementemia|Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 778: Line 853:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Gastrointestinal diseases|Gastrointestinal disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Acute mesenteric ischemia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 790: Line 879:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis C virus]]-associated [[Cryoglobulinemia|cryoglobulinemic vasculitis]]
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cardiovascular diseases|Cardiovascular disease]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Infective Endocarditis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓[[C4A|serum C4]], Positive [[RF]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 809: Line 899:
!
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Palpable [[purpura]], [[Microscopic hematuria]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Henoch-Schönlein purpura|IgA vasculitis (Henoch-Schönlein purpura)]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Leukocytoclastic vasculitis|Leukocytoclastic Vasculitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 832: Line 922:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hypocomplementemia|Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis)]]
! rowspan="6" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Pulmonary disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Langerhans Cell Histiocytosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 841: Line 940:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Lung abscess|Lung Abscess]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 853: Line 965:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Gastrointestinal diseases|Gastrointestinal disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Non small cell lung cancer|Non-Small Cell Lung Cancer]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Acute mesenteric ischemia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 875: Line 986:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cardiovascular diseases|Cardiovascular disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Small cell lung cancer|Small Cell Lung Cancer]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Infective Endocarditis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 886: Line 1,003:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Asthma]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 893: Line 1,021:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Leukocytoclastic vasculitis|Leukocytoclastic Vasculitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Pulmonary Infarction]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 910: Line 1,045:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Renal disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Acute poststreptococcal glomerulonephritis|Acute Poststreptococcal Glomerulonephritis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! rowspan="6" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Pulmonary disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Langerhans Cell Histiocytosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 926: Line 1,067:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! rowspan="9" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hematologic disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hemolytic-uremic syndrome|Hemolytic-Uremic Syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 940: Line 1,093:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Lung abscess|Lung Abscess]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia (CLL)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 949: Line 1,110:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Multiple myeloma|Multiple Myeloma]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 961: Line 1,135:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Non small cell lung cancer|Non-Small Cell Lung Cancer]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hypereosinophilic syndrome|Hypereosinophilic Syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 982: Line 1,156:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Small cell lung cancer|Small Cell Lung Cancer]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Non-Hodgkin lymphoma|Non-Hodgkin Lymphoma]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 992: Line 1,173:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Serum sickness|Serum Sickness]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 999: Line 1,191:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Asthma]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,016: Line 1,215:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Idiopathic thrombocytopenic purpura|Idiopathic Thrombocytopenic Purpura]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Pulmonary Infarction]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,031: Line 1,236:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[B cell lymphoproliferative disease|B cell lymphoproliferative disorder]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,045: Line 1,261:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Renal disease]]
! rowspan="5" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Acute poststreptococcal glomerulonephritis|Acute Poststreptococcal Glomerulonephritis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Sarcoidosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,055: Line 1,279:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Legionella Infections|Legionella Infection]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,067: Line 1,304:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! rowspan="9" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hematologic disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic lupus erythematosus]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hemolytic-uremic syndrome|Hemolytic-Uremic Syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,089: Line 1,325:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia (CLL)]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Rheumatoid arthritis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,099: Line 1,342:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Relapsing polychondritis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
|-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Multiple myeloma|Multiple Myeloma]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,131: Line 1,367:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hypereosinophilic syndrome|Hypereosinophilic Syndrome]]
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Headache
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Fever
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Arthralgia
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Claudication
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Bruit
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |HTN
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Focal neurological disorder
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Biomarker
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |CBC
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |ESR
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Other
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |CT scan
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Angiography
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Ultrasound
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Other
!
! style="background:#4479BA; color: #FFFFFF;" align="center" |Histopathology
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |'''Gold standard'''
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="background:#4479BA; color: #FFFFFF;" align="center" |Additional findings
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Non-Hodgkin lymphoma|Non-Hodgkin Lymphoma]]
! rowspan="5" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Variable-vessel vasculitis
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Behçet's disease|Behçet’s syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,162: Line 1,406:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cogan syndrome|Cogan's syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,169: Line 1,424:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Serum sickness|Serum Sickness]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''[[Red eye]], [[Hearing loss]], [[Vertigo]]'''
|-
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Gastrointestinal diseases|Gastrointestinal disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Inflammatory bowel disease|Inflammatory Bowel Disease]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,185: Line 1,449:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Whipple's disease]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,201: Line 1,470:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Sjögren's syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,215: Line 1,495:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Idiopathic thrombocytopenic purpura|Idiopathic Thrombocytopenic Purpura]]
! rowspan="6" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Single-organ vasculitis
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Primary [[central nervous system]] [[vasculitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Von Willebrand factor (vWF)|von Willebrand factor antigen (vWF)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,223: Line 1,513:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Infectious disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Aspergillosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,236: Line 1,539:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[B cell lymphoproliferative disease|B cell lymphoproliferative disorder]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Histoplasmosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,257: Line 1,560:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! rowspan="5" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Herpes Simplex Encephalitis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Sarcoidosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,267: Line 1,577:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic diseases|Systemic disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Eclampsia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,279: Line 1,603:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Legionella Infections|Legionella Infection]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Fibromuscular dysplasia]]<ref name="pmid17555581" />
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Transforming growth factor β|Transforming growth factor β (TGF-β)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ [[Creatinine|Cr]] or [[Blood urea nitrogen|BUN]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Alternating [[stenosis]] and [[Dilatation|dilatations]] in [[CT angiography]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Stenosis]] in the [[renal arteries]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Luminal narrowing alternating with [[dilatation]] (Beads sign)
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Focal [[concentric]], long-segment [[tubular]] [[stenosis]] or outpouching in [[MRA]]
!
!Fibrodysplastic changes, [[Collagen]] deposition
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Digital subtraction angiography|Digital subtraction angiography (DSA)]] 
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Spontaneous coronary artery dissection|Spontaneous coronary artery dissection (SCAD)]]
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic lupus erythematosus]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Rheumatoid arthritis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Relapsing polychondritis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
! style="background:#4479BA; color: #FFFFFF;" align="center" |Headache
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss
! style="background:#4479BA; color: #FFFFFF;" align="center" |Arthralgia
! style="background:#4479BA; color: #FFFFFF;" align="center" |Claudication
! style="background:#4479BA; color: #FFFFFF;" align="center" |Bruit
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |HTN
! style="background:#4479BA; color: #FFFFFF;" align="center" |Focal neurological disorder
! style="background:#4479BA; color: #FFFFFF;" align="center" |Biomarker
! style="background:#4479BA; color: #FFFFFF;" align="center" |CBC
! style="background:#4479BA; color: #FFFFFF;" align="center" |ESR
! style="background:#4479BA; color: #FFFFFF;" align="center" |Other
! style="background:#4479BA; color: #FFFFFF;" align="center" |CT scan
! style="background:#4479BA; color: #FFFFFF;" align="center" |Angiography
! style="background:#4479BA; color: #FFFFFF;" align="center" |Ultrasound
! style="background:#4479BA; color: #FFFFFF;" align="center" |Other
! style="background:#4479BA; color: #FFFFFF;" align="center" |Histopathology
! style="background:#4479BA; color: #FFFFFF;" align="center" |'''Gold standard'''
! style="background:#4479BA; color: #FFFFFF;" align="center" |Additional findings
|-
! rowspan="5" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Variable-vessel vasculitis
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Behçet's disease|Behçet’s syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cogan syndrome|Cogan's syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Gastrointestinal diseases|Gastrointestinal disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Inflammatory bowel disease|Inflammatory Bowel Disease]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Whipple's disease]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Sjögren's syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! rowspan="6" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Single-organ vasculitis
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Primary [[central nervous system]] [[vasculitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Infectious disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Aspergillosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Histoplasmosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Herpes Simplex Encephalitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic diseases|Systemic disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Eclampsia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Fibromuscular dysplasia|Fibromuscular Dysplasia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
|-
|-
|}
|}

Revision as of 20:35, 29 March 2018

Vasculitis

Overview

Classification

Large-sized vessel vasculitis
Takayasu's Arteritis
Temporal Arteritis
Medium-sized vessel vasculitis
Kawasaki's Disease
Polyarteritis Nodosa
Small-sized vessel vasculitis
Churg-Strauss Syndrome
Cutaneous leukocytoclastic vasculitis
Essential cryoglobulinemic vasculitis
Henoch-Schonlein Purpura
Microscopic polyangiitis
Wegener's Granulomatosis
Variable-sized vessel vasculitis
Sjogren syndrome
Cogan syndrome
Single organ vasculitis
Primary central nervous system angiitis

Causes

Differential Diagnosis

gsEditor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Differential Diagnosis

Abbreviations: ABG= Arterial blood gas, ANP= Atrial natriuretic peptide, BNP= Brain natriuretic peptide, CBC= Complete blood count, COPD= Chronic obstructive pulmonary disease, CRP= C-reactive protein, CT= Computed tomography, CXR= Chest X-ray, DVT= Deep vein thrombosis, ESR= Erythrocyte sedimentation rate, HRCT= High Resolution CT, IgE= Immunoglobulin E, LDH= Lactate dehydrogenase, PCWP= Pulmonary capillary wedge pressure.

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Headache Fever Weight loss Arthralgia Claudication Bruit HTN Focal neurological disorder Biomarker CBC ESR Other CT scan Angiography Ultrasound Other
Large-Vessel Vasculitis Takayasu arteritis[1] + +/- + - + + +/- +/- MMP-3 and MMP-9 Leukocytosis, Anemia CRP Aneurysmal dilatation of the aorta Blood vessel stenosis Circumferential thickening of the arterial wall (Macaroni sign) PET-scan, Cardiac CT Granulomatous inflammation of arteries Arteriography Coronary aneurysm
Giant cell arteritis[2] + - + +/- - - - +/- Pentraxin 3 (PTX3) Normal CRP Stenosis, Occlusion, Dilatation Aneurysm - Mural inflammation in MRA Granulomatous inflammation of arteries Biopsy  Jaw pain and claudication
Neurological disease Cerebral aneurysm[3] + - - - - - +/- + - Normal Normal - Well-defined round, slightly hyperattenuating lesion Bulging out of the main lumen - Heterogeneous signal intensity in MRA Layers of smooth muscle cells, Intact endothelium Digital subtraction angiography (DSA) Nausea, Vomiting
Neurofibromatosis type 1[4] +/- - +/- - - - + + NF1 mutated gene Normal Normal Neurofibromin gene Bone abnormalities  Optical coherence tomography angiography (OCTA) - Optic nerve gliomas in MRI Elongated spindle-shaped cells in neurofibromas NIH diagnostic criteria Cafe au Lait spot
Neurofibromatosis type 2[5] +/- - +/- - +/- - - + NF2 mutated gene Normal Normal Schwannomin Meningioma, Schwannoma, Ependymoma Fluorescein angiography showed retinal hamartoma Localized schwannomas in nerve ultrasound Schwannoma in MRI Encapsulated biphasic nerve sheath tumor NIH diagnostic criteria Hearing loss, Vision loss
Systemic disease Fibromuscular dysplasia[6] + - +/- + + + + +/- Transforming growth factor β (TGF-β) Normal Cr or BUN Alternating stenosis and dilatations in CT angiography Stenosis in the renal arteries Luminal narrowing alternating with dilatation (Beads sign) Focal concentric, long-segment tubular stenosis or outpouching in MRA Fibrodysplastic changes, Collagen deposition Digital subtraction angiography (DSA)  Spontaneous coronary artery dissection (SCAD)
Ehlers-Danlos syndrome[7] - - - + +/- +/- - +/- TGF-β Normal Normal Cultured skin fibroblasts Multiple vascular segments with aneurysms and dissections Dissection of the posterolateral branch of the left circumflex coronary artery (LCx) Visceral arteries abnormality Vascular abnormalities in MRA Thin and rare collagen bundles in the dermis History and physical examination Bleeding, Bruisability, Heart murmur
Polymyalgia rheumatica (PMR)[8] + - +/- + - - - - Plasma fibrinogen Normocytic, normochromic anemia CRP Periodontoid localization of calcification Vessel wall thickening, Increased mural contrast enhancement Subacromial or subdeltoid bursitis High F-FDG accumulation around the joints in FDG PET-CT Small angular fibers, Pyknotic nuclear clumps, or target-targetoid fibers - Joint stiffness, Fatigue
Amyloidosis[9] +/- - - +/- +/- - + + Immunoglobulin light chain(Amyloid) Anemia Normal Cr or BUN,

ALT or AST

Diffusely hypoattenuating and enlarged liver Amyloid deposition in the media and adventitia of small arteries  Solid organs increased echogenicity Tc-DPD for cardiac amyloid deposits Extracellular deposition of fibrillar proteins Biopsy Cardiomegaly, Dyspnea
Diseases Headache Fever Weight loss Arthralgia Claudication Bruit HTN Focal neurological disorder Biomarker CBC ESR Other CT scan Angiography Ultrasound Other Histopathology Gold standard Additional findings
Medium-Vessel Vasculitis Polyarteritis nodosa[10] + + + + + + +/- +/- LAMP-2 protein autoantibodies Leukocytosis, Normochromic anemia, Thrombocytosis Cr or BUN,

ALT or AST, Proteinuria

Focal regions of infarction or hemorrhage Multiple microaneurysms, Hemorrhage due to focal rupture, Occlusion Aneurysms and renal arteriovenous fistula in color Doppler sonography - Necrotizing inflammatory lesions Angiography Sudden weight loss, Abdominal pain
Hepatitis B virus-associated polyarteritis nodosa[11] +/- +/- + + +/- +/- + - HBsAg Leukocytosis, Normochromic anemia, Thrombocytosis ALT or AST Focal regions of infarction or hemorrhage Microaneurysms in mesenteric artery Aneurysms and renal arteriovenous fistula in color Doppler sonography - Necrotizing inflammatory lesions Angiography Peripheral neuropathy, Livedo reticularis
Kawasaki disease[12] - + +/- + + - +/- - NT-proBNP, Meprin A, Filamin C Normochromic anemia, ↑WBC with a left shift, Thrombocytosis  Acute-phase reactants, ↓Cholesterol, ↓HDL, ↓ApolipoA Coronary artery calcifications Coronary artery aneurysms, stenosis or occlusion Coronary artery anomaly in echocardiography Electron beam CT (EBCT) Acute destruction of the media by neutrophils, with loss of elastic fibers History and physical examination Diarrhea, Vomiting
Infectious disease Parvovirus B19 infection[13] + + + + - - - +/- B19 DNA, ↓Reticulocyte count Anemia anti–parvovirus B19 IgM - - Hydrops in fetal ultrasonography - - B19 DNA Purpuric rash, Erythema multiforme
Scarlet fever[14] + + +/- + - - - - Antistreptolysin-O (ASO) titers Leukocytosis CRP Thickened pulmonary markings if pneumonia - - - Sparse neutrophilic perivascular infiltrate History and physical examination Sand-paper rashes, Sore throat
Toxic shock syndrome[15] + + + + - - - +/- Procalcitonin Leukocytosis with left shift Myoglobinuria, Sterile pyuria Acute respiratory distress syndrome - - - Necrolysis of keratinocytes in epidermis, Perivascular lymphocytic infiltrate Clinical criteria Peeling or rashes, Organ dysfunction
Mononucleosis[16] + + + + - - - - EBV DNA Atypical lymphocyte Heterophile antibodies CNS involvement - Splenomegaly Encephalitis in MRI Lymphoproliferative response in oropharynx, Lymphocytic infiltration in spleen Heterophile antibody test Splenomegaly, Palatal petechiae
Leptospirosis[17] + + + + +/- - - - IL-6, IL-8 and IL-10 Anemia - Cr or BUN,

ALT or AST, Proteinuria

 Diffuse alveolar hemorrhage - - - Toxin-mediated break down of endothelial cell membranes of capillaries Culture and the microscopic agglutination test Red eyes, Skin rash
Lyme Disease[18] +/- + +/- + +/- - - - CXCL9 (MIG), CXCL10 (IP-10) and CCL19 (MIP3B) Leukopenia, Thrombocytopenia - Microscopic hematuria, Proteinuria, ↑ALT or AST Punctate lesions in periventricular white matter in brain SPECT - - - Acrodermatitis chronica atrophicans Serologic tests Erythema migrans
Measles[19] +/- + +/- + - - - - Measles IgM Leukopenia, Lymphocytosis, Thrombocytopenia - ALT or AST Pneumonia - - CXR Spongiosis and vesiculation in the epidermis with scattered dyskeratotic keratinocytes PCR Generalized rash, Cough, Coryza, or Conjunctivitis
Rocky Mountain Spotted Fever[20] + + + + - - - - R rickettsii serology Thrombocytopenia, Anemia  - ALT or AST, Hyponatremia Infarction, edema, and meningeal enhancement - Myocardial or conduction abnormalities in echocardiography - Immunofluorescent or immunoperoxidase staining of R rickettsii Clinical criteria and tick exposure Rash on the palms and soles
Staphylococcal Scalded Skin Syndrome[21] + + + + - - +/- +/- Anti exfoliatin and anti alpha-toxin antibodies Leukocytosis with left shift Blood culture Pneumonia - - - Intraepidermal blister, dense superficial perivascular lymphohistiocytic infiltrate  Blood culture and clinical findings Widespread skin erythema, fluid-filled blisters
Toxic Epidermal Necrolysis[22] - + + - - - - +/- MicroRNA-124 Normochromic normocytic anemia, Eosinophilia Fluid loss and electrolyte abnormalities Tracheobronchial inflammation - - - Necrotic keratinocytes with full-thickness epithelial necrosis Histopathology and clinical findings Erythematous macular rash with purpuric centers
Cardiovascular disease Atrial Myxoma[23] - - +/- - - - - +/- Calretinin Mild anemia, Leukocytosis IL-6 Atrial filling defect larger than a thrombus - Tumor location, size, attachment, and mobility in echocardiography Size, shape, and surface characteristics in MRI Lipidic cells embedded in a vascular myxoid stroma Echocardiography Dyspnea on exertion, Syncope
Cholesterol Embolism[24] +/- +/- - - + - - + IL-5 Eosinophilia, Leukocytosis   Eosinophiluria Thoracic and abdominal aortic sources of embolism Atheroembolism in abdominal aorta and the lower extremity arteries Excluding an intracardiac source of embolism with echocardiography  - Birefringent crystals or biconvex needle-shaped ghostly clefts within the arterial lumen Angiography  Livedo reticularis,

Ischemic patches

Segmental arterial mediolysis[25] + - - - + + + +/- - Leukocytosis - - Visceral artery aneurysm in CT angiography Alternating aneurysms and stenoses (beading) Retroperitoneal hematoma - Disruption of the smooth muscle in the media Angiography  Hematuria, Ischemic colitis
Systemic disease Antiphospholipid Syndrome[26] + + - - - - - +/- Antiphospholipid antibodies Thrombocytopenia, Hemolytic anemia - Lupus anticoagulant (LA) Stroke,

Pulmonary embolism, Budd-Chiari syndrome

Thrombus in major vessels Valve thickening, vegetations, or insufficiency in echocardiography - Noninflammatory bland thrombosis without perivascular inflammation Hx of thrombosis and antiphospholipid antibodies Miscarriage, Pulmonary hypertension
Juvenile Idiopathic Arthritis[27] - - - + +/- - - - Rheumatoid factor (RF), S100A12 Lymphocytosis, Thrombocytopenia Myeloid-related proteins 8/14 (MRP8/14) Synovial hypertrophy, Joint effusions Cerebral vasculitis Inflamed synovium Bone scanning Vascular congestion, RBC extravasation, Venular lumen occlusion Conventional radiography Evanescent rash, Dactylitis 
Diseases Headache Fever Weight loss Arthralgia Claudication Bruit HTN Focal neurological disorder Biomarker CBC ESR Other CT scan Angiography Ultrasound Other Histopathology Gold standard Additional findings
Small-Vessel Vasculitis ANCA-associated vasculitis Microscopic polyangiitis + - - +/- - - - + Anti-PR3 antibody, Anti-MPO antibody
Granulomatosis with polyangiitis (Wegener’s) + +/- +/- - - - - + Anti-PR3 antibody, Anti-MPO antibody
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) +/- - - + - - - + Eotaxin-3
Hydralazine-associated ANCA-associated vasculitis - - - + - - - +/-
Immune complex small-vessel vasculitis Anti-glomerular basement membrane disease - +/- - - - - + -
Cryoglobulinemic vasculitis +/- +/- - + +/- - - - C4 component
Hepatitis C virus-associated cryoglobulinemic vasculitis +/- +/- + + - - + +/- HCV RNA Serum C4, Positive RF Palpable purpura, Microscopic hematuria
IgA vasculitis (Henoch-Schönlein purpura) - - + + - - - - Hematuria
Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis) - - +/- + - - - -
Gastrointestinal disease Acute mesenteric ischemia - +/- - - - - - -
Cardiovascular disease Infective Endocarditis + + + - - - - +
Leukocytoclastic Vasculitis + - - + - - - +
Pulmonary disease Langerhans Cell Histiocytosis +/- - - + - - - -
Lung Abscess - + + - - - - -
Non-Small Cell Lung Cancer - +/- + - - - - +/-
Small Cell Lung Cancer - +/- + - - - - +/-
Asthma - + + - - - - -
Pulmonary Infarction +/- - - - - - + -
Renal disease Acute Poststreptococcal Glomerulonephritis - - - + - - + +/-
Hematologic disease Hemolytic-Uremic Syndrome + + - + - - + +
Chronic Lymphocytic Leukemia (CLL) + + + + +/- - - +/-
Multiple Myeloma + - + + + + +/- +/-
Hypereosinophilic Syndrome +/- +/- - - - - - -
Non-Hodgkin Lymphoma + + + + +/- +/- +/- +/-
Serum Sickness + + - +/- +/- - - +/-
Disseminated Intravascular Coagulation +/- + - +/- - - + +
Idiopathic Thrombocytopenic Purpura + +/- - + - - - +
B cell lymphoproliferative disorder + + + + +/- - - +
Systemic disease Sarcoidosis + + + + - - - +/-
Legionella Infection + + + + - - - +/-
Systemic lupus erythematosus + + + + - - + +
Rheumatoid arthritis - - + + + + - -
Relapsing polychondritis - +/- +/- + + - - -
Diseases Headache Fever Weight loss Arthralgia Claudication Bruit HTN Focal neurological disorder Biomarker CBC ESR Other CT scan Angiography Ultrasound Other Histopathology Gold standard Additional findings
Variable-vessel vasculitis Behçet’s syndrome - - - + - - +/- -
Cogan's syndrome +/- - - +/- - - - + Red eye, Hearing loss, Vertigo
Gastrointestinal disease Inflammatory Bowel Disease +/- + + + + - - -
Whipple's disease + +/- + + + + + +
Sjögren's syndrome - - +/- + - - - -
Single-organ vasculitis Primary central nervous system vasculitis + + + - + - + + von Willebrand factor antigen (vWF)
Infectious disease Aspergillosis + + + - - - - +
Histoplasmosis + + + + + - - +
Herpes Simplex Encephalitis + + - - - - - +
Systemic disease Eclampsia + + - + - - + +
Fibromuscular dysplasia[6] + - +/- + + + + +/- Transforming growth factor β (TGF-β) Normal Cr or BUN Alternating stenosis and dilatations in CT angiography Stenosis in the renal arteries Luminal narrowing alternating with dilatation (Beads sign) Focal concentric, long-segment tubular stenosis or outpouching in MRA Fibrodysplastic changes, Collagen deposition Digital subtraction angiography (DSA)  Spontaneous coronary artery dissection (SCAD)

References

  1. Vaideeswar P, Deshpande JR (2013). "Pathology of Takayasu arteritis: A brief review". Ann Pediatr Cardiol. 6 (1): 52–8. doi:10.4103/0974-2069.107235. PMC 3634248. PMID 23626437.
  2. Calvo-Romero JM (2003). "Giant cell arteritis". Postgrad Med J. 79 (935): 511–5. PMC 1742823. PMID 13679546.
  3. Stafa A, Leonardi M (2008). "Role of neuroradiology in evaluating cerebral aneurysms". Interv Neuroradiol. 14 Suppl 1: 23–37. doi:10.1177/15910199080140S106. PMC 3328052. PMID 20557771.
  4. Cassiman C, Casteels I, Stalmans P, Legius E, Jacob J (2017). "Optical Coherence Tomography Angiography of Retinal Microvascular Changes Overlying Choroidal Nodules in Neurofibromatosis Type 1". Case Rep Ophthalmol. 8 (1): 214–220. doi:10.1159/000469702. PMC 5422752. PMID 28512424.
  5. Evans, D G. R (2000). "Neurofibromatosis type 2". Journal of Medical Genetics. 37 (12): 897–904. doi:10.1136/jmg.37.12.897. ISSN 1468-6244.
  6. 6.0 6.1 Plouin PF, Perdu J, La Batide-Alanore A, Boutouyrie P, Gimenez-Roqueplo AP, Jeunemaitre X (2007). "Fibromuscular dysplasia". Orphanet J Rare Dis. 2: 28. doi:10.1186/1750-1172-2-28. PMC 1899482. PMID 17555581.
  7. Gazit Y, Jacob G, Grahame R (2016). "Ehlers-Danlos Syndrome-Hypermobility Type: A Much Neglected Multisystemic Disorder". Rambam Maimonides Med J. 7 (4). doi:10.5041/RMMJ.10261. PMC 5101008. PMID 27824552.
  8. Michet CJ, Matteson EL (2008). "Polymyalgia rheumatica". BMJ. 336 (7647): 765–9. doi:10.1136/bmj.39514.653588.80. PMC 2287267. PMID 18390527.
  9. Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
  10. Howard T, Ahmad K, Swanson JA, Misra S (2014). "Polyarteritis nodosa". Tech Vasc Interv Radiol. 17 (4): 247–51. doi:10.1053/j.tvir.2014.11.005. PMC 4363102. PMID 25770638.
  11. Sharma A, Sharma K (September 2013). "Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polyarteritis nodosa and hepatitis C virus associated cryoglobulinemic vasculitis". J Clin Exp Hepatol. 3 (3): 204–12. doi:10.1016/j.jceh.2013.06.001. PMC 4216827. PMID 25755502.
  12. Takahashi K, Oharaseki T, Yokouchi Y (2011). "Pathogenesis of Kawasaki disease". Clin Exp Immunol. 164 Suppl 1: 20–2. doi:10.1111/j.1365-2249.2011.04361.x. PMC 3095860. PMID 21447126.
  13. Heegaard ED, Brown KE (2002). "Human parvovirus B19". Clin Microbiol Rev. 15 (3): 485–505. PMC 118081. PMID 12097253.
  14. Basetti S, Hodgson J, Rawson TM, Majeed A (2017). "Scarlet fever: a guide for general practitioners". London J Prim Care (Abingdon). 9 (5): 77–79. doi:10.1080/17571472.2017.1365677. PMC 5649319. PMID 29081840.
  15. Vostral SL (2011). "Rely and Toxic Shock Syndrome: a technological health crisis". Yale J Biol Med. 84 (4): 447–59. PMC 3238331. PMID 22180682.
  16. Balfour HH, Dunmire SK, Hogquist KA (2015). "Infectious mononucleosis". Clin Transl Immunology. 4 (2): e33. doi:10.1038/cti.2015.1. PMC 4346501. PMID 25774295.
  17. Levett PN (April 2001). "Leptospirosis". Clin. Microbiol. Rev. 14 (2): 296–326. doi:10.1128/CMR.14.2.296-326.2001. PMC 88975. PMID 11292640.
  18. Biesiada G, Czepiel J, Leśniak MR, Garlicki A, Mach T (2012). "Lyme disease: review". Arch Med Sci. 8 (6): 978–82. doi:10.5114/aoms.2012.30948. PMC 3542482. PMID 23319969.
  19. White SJ, Boldt KL, Holditch SJ, Poland GA, Jacobson RM (2012). "Measles, mumps, and rubella". Clin Obstet Gynecol. 55 (2): 550–9. doi:10.1097/GRF.0b013e31824df256. PMC 3334858. PMID 22510638.
  20. Walker DH (1989). "Rocky Mountain spotted fever: a disease in need of microbiological concern". Clin Microbiol Rev. 2 (3): 227–40. PMC 358117. PMID 2504480.
  21. Mishra AK, Yadav P, Mishra A (2016). "A Systemic Review on Staphylococcal Scalded Skin Syndrome (SSSS): A Rare and Critical Disease of Neonates". Open Microbiol J. 10: 150–9. doi:10.2174/1874285801610010150. PMC 5012080. PMID 27651848.
  22. Hoetzenecker W, Mehra T, Saulite I, Glatz M, Schmid-Grendelmeier P, Guenova E; et al. (2016). "Toxic epidermal necrolysis". F1000Res. 5. doi:10.12688/f1000research.7574.1. PMC 4879934. PMID 27239294.
  23. MacGowan SW, Sidhu P, Aherne T, Luke D, Wood AE, Neligan MC, McGovern E (June 1993). "Atrial myxoma: national incidence, diagnosis and surgical management". Ir J Med Sci. 162 (6): 223–6. PMID 8407260.
  24. Avci G, Akoz T, Gul AE (2009). "Cutaneous cholesterol embolization". J Dermatol Case Rep. 3 (2): 27–9. doi:10.3315/jdcr.2009.1031. PMC 3157794. PMID 21886725.
  25. Chao, Christine (2009). "Segmental Arterial Mediolysis". Seminars in Interventional Radiology. 26 (03): 224–232. doi:10.1055/s-0029-1225666. ISSN 0739-9529.
  26. Chaturvedi S, McCrae KR (2015). "The antiphospholipid syndrome: still an enigma". Hematology Am Soc Hematol Educ Program. 2015: 53–60. doi:10.1182/asheducation-2015.1.53. PMC 4877624. PMID 26637701.
  27. Espinosa M, Gottlieb BS (July 2012). "Juvenile idiopathic arthritis". Pediatr Rev. 33 (7): 303–13. doi:10.1542/pir.33-7-303. PMID 22753788.

Template:WH Template:WS